The margin is thin and there's no do-over. We build you a custom, real-world-data analysis that gets site selection right from the start — the right patients, and the sites that will actually enroll them.
In biotech, you get one real shot. Pick the wrong sites and it surfaces as delays, missed enrollment, rescue sites spun up mid-study, and protocol amendments you can't afford. We take that risk off the table before you commit — so the science gets its fair shot.
We model your protocol against real patients — isolating each variable, showing where you'd lose people, and pinpointing the criteria you can safely loosen to open the enrollment pool without compromising the study.
We show exactly where your eligible patients are — even for hard, rare populations — and which sites can reach them. Including the uncomfortable truth: sometimes the marquee KOL site isn't the one that will enroll. Better to know first. We can promise the patients are there because we can actually see all of them — every institution, the full journey, not a snapshot.
Enrollment is where trials slip. We take it off the table so you move toward approval without the costly snags.
Design smarter, find the right patients and sites, and de-risk the enrollment your timeline depends on.